Maynard Um
-
-
-
-
-
-
-
Simulations Plus (SLP) Fairly Valued Given Modest FY26-27 Growth Estimates - Citizens
-
-
-
-
-
-
-
Simulations Plus validates AI drug design with Polish academy study
-
-
-
-
-
-
-
Simulations Plus (SLP) Announces Rescheduling of Q3 Earnings Release
-
-
-
-
-
-
-
Simulations Plus (SLP) Tops Q2 EPS by 5c; offers guidance
-
-
-
-
-
-
-
Simulations Plus (SLP) Tops Q4 EPS by 2c, provides guidance
-
-
-
-
-
-
-
William Blair Starts Simulations Plus (SLP) at Outperform
-
-
-
341,965 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

